Cenos is developing a blood-brain barrier shuttle platform for the treatment of neurological diseases of high unmet need. We combine innovative delivery technologies with comprehensive therapeutic development expertise to drive meaningful impact for patients. Focus/Therapeutic Area: Neuro Stage/Status: Seed Website: —
Cenos Therapeutics Read More »
Clasp is pioneering precision in immuno-oncology through next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations common across hard-to-treat cancers. With their unique properties, our TCEs are adaptable for application across a variety of cancers with high unmet need. Focus/Therapeutic Area: Oncology Stage/Status: Series A Website: https://www.clasptx.com/
Clasp Therapeutics Read More »
Advancing off-the-shelf dopamine neuron replacement therapies as a disease-modifying and potentially curative treatment for neurological disorders. Our proprietary platform leverages a novel approach to treating central nervous system disorders, such as Parkinson’s disease, by replacing neurons lost due to neurodegeneration. Focus/Therapeutic Area: Neuro Stage/Status: Series A Website: https://www.kenaitx.com
Kenai Therapeutics Read More »
